CLA4_CLACD
ID CLA4_CLACD Reviewed; 594 AA.
AC A0A120HYZ1;
DT 07-SEP-2016, integrated into UniProtKB/Swiss-Prot.
DT 13-APR-2016, sequence version 1.
DT 25-MAY-2022, entry version 18.
DE RecName: Full=Lysine--tRNA ligase cla4 {ECO:0000305};
DE EC=6.1.1.6;
DE AltName: Full=Cladosporin biosynthesis cluster protein 4 {ECO:0000303|PubMed:26783060};
DE AltName: Full=Lysyl-tRNA synthetase {ECO:0000303|PubMed:26783060};
DE Short=LysRS {ECO:0000305};
GN Name=cla4 {ECO:0000303|PubMed:26783060};
OS Cladosporium cladosporioides.
OC Eukaryota; Fungi; Dikarya; Ascomycota; Pezizomycotina; Dothideomycetes;
OC Dothideomycetidae; Cladosporiales; Cladosporiaceae; Cladosporium.
OX NCBI_TaxID=29917;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA], AND FUNCTION.
RX PubMed=26783060; DOI=10.1002/anie.201509345;
RA Cochrane R.V., Sanichar R., Lambkin G.R., Reiz B., Xu W., Tang Y.,
RA Vederas J.C.;
RT "Production of new cladosporin analogues by reconstitution of the
RT polyketide synthases responsible for the biosynthesis of this antimalarial
RT agent.";
RL Angew. Chem. Int. Ed. 55:664-668(2016).
CC -!- FUNCTION: Involved in self-resistance to cladosporin since this product
CC is an inhibitor of lysyl-tRNA synthetase. Cla4 may not be inhibited by
CC cladosporin, thereby imparting cladosporin resistance
CC (PubMed:26783060). When cladosporin biosynthesis is switched on,
CC transcription of cla4 will then be necessary for continued protein
CC synthesis in C.cladosporioides (PubMed:26783060).
CC {ECO:0000269|PubMed:26783060}.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=ATP + L-lysine + tRNA(Lys) = AMP + diphosphate + L-lysyl-
CC tRNA(Lys); Xref=Rhea:RHEA:20792, Rhea:RHEA-COMP:9696, Rhea:RHEA-
CC COMP:9697, ChEBI:CHEBI:30616, ChEBI:CHEBI:32551, ChEBI:CHEBI:33019,
CC ChEBI:CHEBI:78442, ChEBI:CHEBI:78529, ChEBI:CHEBI:456215; EC=6.1.1.6;
CC Evidence={ECO:0000250|UniProtKB:P15180};
CC -!- SUBUNIT: Homodimer. {ECO:0000250|UniProtKB:P15180}.
CC -!- SIMILARITY: Belongs to the class-II aminoacyl-tRNA synthetase family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; KT037693; AMB51801.1; -; mRNA.
DR AlphaFoldDB; A0A120HYZ1; -.
DR SMR; A0A120HYZ1; -.
DR GO; GO:0005737; C:cytoplasm; IEA:InterPro.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0004824; F:lysine-tRNA ligase activity; IEA:UniProtKB-EC.
DR GO; GO:0003676; F:nucleic acid binding; IEA:InterPro.
DR GO; GO:0006430; P:lysyl-tRNA aminoacylation; IEA:InterPro.
DR CDD; cd00775; LysRS_core; 1.
DR CDD; cd04322; LysRS_N; 1.
DR Gene3D; 2.40.50.140; -; 1.
DR Gene3D; 3.30.930.10; -; 1.
DR HAMAP; MF_00252; Lys_tRNA_synth_class2; 1.
DR InterPro; IPR004364; Aa-tRNA-synt_II.
DR InterPro; IPR006195; aa-tRNA-synth_II.
DR InterPro; IPR045864; aa-tRNA-synth_II/BPL/LPL.
DR InterPro; IPR002313; Lys-tRNA-ligase_II.
DR InterPro; IPR034762; Lys-tRNA-ligase_II_bac/euk.
DR InterPro; IPR044136; Lys-tRNA-ligase_II_N.
DR InterPro; IPR018149; Lys-tRNA-synth_II_C.
DR InterPro; IPR012340; NA-bd_OB-fold.
DR InterPro; IPR004365; NA-bd_OB_tRNA.
DR Pfam; PF00152; tRNA-synt_2; 1.
DR Pfam; PF01336; tRNA_anti-codon; 1.
DR PIRSF; PIRSF039101; LysRS2; 1.
DR PRINTS; PR00982; TRNASYNTHLYS.
DR SUPFAM; SSF50249; SSF50249; 1.
DR SUPFAM; SSF55681; SSF55681; 1.
DR TIGRFAMs; TIGR00499; lysS_bact; 1.
DR PROSITE; PS50862; AA_TRNA_LIGASE_II; 1.
PE 2: Evidence at transcript level;
KW Aminoacyl-tRNA synthetase; ATP-binding; Ligase; Nucleotide-binding;
KW Protein biosynthesis.
FT CHAIN 1..594
FT /note="Lysine--tRNA ligase cla4"
FT /id="PRO_0000437073"
FT REGION 1..62
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 19..47
FT /note="Basic and acidic residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 48..62
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
SQ SEQUENCE 594 AA; 67601 MW; 83F8506AC921AB07 CRC64;
MADPGAVKET VLLLDEPTGE KVSKTELKKR LKSRAKEAEK QKKAATAPTK IQKETSSEQD
EANLSAHQYF EIRSNRINKL RETKNSYPYP HKFEVTNDLR DFLTVYKNLA KGEERTDVPI
RIAGRIYTKR VSGNKLVFYD IRAEGVKVQV MCQAQNSTTG FEEQHEVLRR GDIVGIVGFP
GRTSPKTRDN GELSIFATQV VLLSPCLHAL PSEHYGFQDK EQRFRQRYLD LIINDRPRQI
FRTRAKIVSY LRSYLDSRDF TEVETPMMNA IAGGATASPF VTHHNDLKRD LFMRVAPELY
LKMLVVGGLE RVYEIGKQFR NEGIDLTHSP EFTTCEFYQA YADYNDLMAM TEDLISSMVK
HITGGYETTF ESQTGQVYTI NWQSPWKRID MIPALEEACG DKFPPGDQLH TPEAGTFLKE
MLKKMKVECT PPLTNARMLD KLVGEFVEDK CINPTFVTGH PQMMSPLAKA HRDTPGICER
FEVFVTTKEL LNAYTELNDP FDQRMRFEEQ ANQKAQGDDE AQMVDENFCQ ALEYGLPPTG
GWGMGIDRLT MFLTNNYSIK EVLAFPMMKD DKADGEKKEA IVKTGTAEDG SVQL